KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Average (2018 - 2025)

Historic Equity Average for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $871.8 million.

  • Vir Biotechnology's Equity Average fell 3480.51% to $871.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $871.8 million, marking a year-over-year decrease of 3480.51%. This contributed to the annual value of $1.4 billion for FY2024, which is 2528.7% down from last year.
  • As of Q3 2025, Vir Biotechnology's Equity Average stood at $871.8 million, which was down 3480.51% from $995.6 million recorded in Q2 2025.
  • Vir Biotechnology's 5-year Equity Average high stood at $2.1 billion for Q4 2022, and its period low was $683.9 million during Q1 2021.
  • In the last 5 years, Vir Biotechnology's Equity Average had a median value of $1.5 billion in 2024 and averaged $1.4 billion.
  • In the last 5 years, Vir Biotechnology's Equity Average surged by 18474.35% in 2022 and then tumbled by 3480.51% in 2025.
  • Over the past 5 years, Vir Biotechnology's Equity Average (Quarter) stood at $1.2 billion in 2021, then surged by 83.17% to $2.1 billion in 2022, then decreased by 22.77% to $1.6 billion in 2023, then fell by 26.77% to $1.2 billion in 2024, then fell by 27.08% to $871.8 million in 2025.
  • Its Equity Average was $871.8 million in Q3 2025, compared to $995.6 million in Q2 2025 and $1.1 billion in Q1 2025.